Targeting SOST using a small-molecule compound retards breast cancer bone metastasis

[1]  Shuaijian Ni,et al.  Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation , 2022, Nature Communications.

[2]  Rafael Riudavets Puig,et al.  JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles , 2021, Nucleic Acids Res..

[3]  P. A. Valiente,et al.  gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. , 2021, Journal of chemical theory and computation.

[4]  K. Forchhammer,et al.  Kinetic Analysis of a Protein-protein Complex to Determine its Dissociation Constant (KD) and the Effective Concentration (EC50) of an Interplaying Effector Molecule Using Bio-layer Interferometry. , 2021, Bio-protocol.

[5]  M. Beckmann,et al.  Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. , 2021, JAMA oncology.

[6]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[7]  A. Padhani,et al.  Bone metastases , 2020, Nature Reviews Disease Primers.

[8]  Caitlin Prather,et al.  Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis. , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  E. Hesse,et al.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. , 2019, JCI insight.

[10]  Jacques P. Brown,et al.  Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  S. Sousa,et al.  Bone-Targeted Therapies in Cancer-Induced Bone Disease , 2018, Calcified Tissue International.

[12]  ChangZhen Liu,et al.  Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer , 2017, Scientific Reports.

[13]  Nuno Bonito,et al.  Bone Metastases: An Overview , 2017, Oncology reviews.

[14]  J. Bilezikian,et al.  Romosozumab for the treatment of osteoporosis , 2017, Expert opinion on biological therapy.

[15]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[16]  D. Scott,et al.  Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.

[17]  S. Papapoulos,et al.  Sclerostin Inhibition in the Management of Osteoporosis , 2016, Calcified Tissue International.

[18]  R. Jain,et al.  Using tumour phylogenetics to identify the roots of metastasis in humans , 2015, Nature Reviews Clinical Oncology.

[19]  Dima Kozakov,et al.  The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins , 2015, Nature Protocols.

[20]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[21]  Renu Malhotra,et al.  IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples , 2014, PloS one.

[22]  M. Drake.  Osteoporosis and Cancer , 2013, Current Osteoporosis Reports.

[23]  G. Salzano,et al.  Bisphosphonates and Cancer: What Opportunities from Nanotechnology? , 2013, Journal of drug delivery.

[24]  Yu Liu,et al.  FIPSDock: A new molecular docking technique driven by fully informed swarm optimization algorithm , 2013, J. Comput. Chem..

[25]  E. Kastritis,et al.  Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy , 2012, International journal of cancer.

[26]  Harry Jubb,et al.  Structural biology and drug discovery for protein-protein interactions. , 2012, Trends in pharmacological sciences.

[27]  T. Blundell,et al.  Structural biology and drug discovery of difficult targets: the limits of ligandability. , 2012, Chemistry & biology.

[28]  Dima Kozakov,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[29]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[30]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[31]  E. Lewiecki.  Sclerostin: a novel target for intervention in the treatment of osteoporosis. , 2011, Discovery medicine.

[32]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Löwik,et al.  Sclerostin: Current Knowledge and Future Perspectives , 2010, Calcified Tissue International.

[34]  P. ten Dijke,et al.  SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. , 2005, Cytokine & growth factor reviews.

[35]  W. Gerald,et al.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.

[36]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  O. Fromigué,et al.  Bisphosphonates Induce Breast Cancer Cell Death In Vitro , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.